Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03602079
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
Klus Pharma Inc.

Tracking Information
First Submitted Date  ICMJE July 6, 2018
First Posted Date  ICMJE July 26, 2018
Last Update Posted Date March 13, 2019
Actual Study Start Date  ICMJE July 16, 2018
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 25, 2018)
  • Phase I: Maximum Tolerated Dose [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    Number of patients with dose limiting toxicities
  • Phase II: Percentage of patients with an Objective Response Rate (ORR) [Complete Response (CR) + Partial Response (PR)] [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    Objective Response Rate as determined by RECIST which will be complete response (CR) + partial response (PR)
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03602079 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 25, 2018)
  • Phase I: Number of patients with Dose Limiting Toxicities [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  • Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. [ Time Frame: Every 3 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  • Phase I: Number of participants who developed measurable anti-drug antibodies [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  • Phase II: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  • Phase II: Duration of response (DOR) in patients who responded as determined by RECIST [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  • Phase II: Number of participants who developed measurable anti-drug antibodies [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
  • Phase II: Progression Free Survival (PFS) [ Time Frame: 2 years from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    Kaplan Meier Curve for survival without progression in patients who responded to treatment
  • Phase II: Overall Survival (OS) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
    Kaplan Meier Curve for survival in all enrolled patients
  • Phase I and II: Phase I and II Maximum observed serum or plasma concentration (Cmax). [ Time Frame: 84 Days from date of first dose ]
  • Phase I and II: Clearance (CL). [ Time Frame: 84 Days from date of first dose ]
  • Phase I and II: Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-∞]). [ Time Frame: 84 Days from date of first dose ]
  • Phase I and II: Terminal phase elimination half life (t½). [ Time Frame: 84 Days from date of first dose ]
  • Phase I and II: Volume of distribution at terminal phase (Vz). [ Time Frame: 84 Days from date of first dose ]
  • Phase I and II: Volume of distribution at steady state (Vss). [ Time Frame: 84 Days from date of first dose ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Official Title  ICMJE A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Brief Summary Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.
Detailed Description This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing (NGS) or HER2 expression, defined as at least 1+ by validated immunohistochemistry (IHC) test. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. Patients will receive study drug as a single IV infusion at the prescribed dose level in each treatment cycle. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • HER2-positive Breast Cancer
  • HER2 Gene Mutation
  • HER-2 Gene Amplification
  • HER2 Positive Gastric Cancer
  • Salivary Gland Cancer
  • Salivary Gland Tumor
  • Salivary Gland Carcinoma
  • Salivary Gland Neoplasms
  • Lung Cancer
  • Colo-rectal Cancer
  • Rare Diseases
  • Solid Tumor
  • Recurrent Gastric Cancer
  • Recurrent Colon Cancer
  • Recurrent Breast Cancer
  • Head and Neck Cancer
  • Head and Neck Carcinoma
  • Bladder Cancer
  • Cervical Cancer
  • Liver Cancer
  • Bile Duct Cancer
  • Urologic Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Recurrent Prostate Cancer
  • Rectal Cancer
  • Recurrent Ovarian Carcinoma
  • Recurrent Renal Cell Cancer
  • Rectal Cancer Stage II
  • Rectal Cancer Stage I
  • Rectal Cancer Stage III
  • Skin Cancer
  • Mouth Cancer
  • Lip Cancer Stage I
  • Tongue Cancer
  • Breast Neoplasm Malignant Primary
  • Larynx Cancer
  • Tonsil Cancer
  • Palate Cancer
  • Mucoepidermoid Carcinoma
  • Primary Peritoneal Carcinoma
  • Mucinous Adenocarcinoma Gastric
  • Mucinous Breast Cancer Recurrent
  • Cholangiocarcinoma
Intervention  ICMJE Drug: A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Study Arms  ICMJE
  • Experimental: Phase I: Dose Escalation
    Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
    Intervention: Drug: A166
  • Experimental: Phase II: • Cohort 1
    HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
    Intervention: Drug: A166
  • Experimental: Phase II: • Cohort 2
    HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
    Intervention: Drug: A166
  • Experimental: Phase II: • Cohort 3
    HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
    Intervention: Drug: A166
  • Experimental: Phase II: • Cohort 4
    All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
    Intervention: Drug: A166
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 25, 2018)
82
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 2021
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Phase I

Patients must meet the following criteria for inclusion into the study:

  1. Patients must be able to provide documented voluntary informed consent.
  2. Male or female patient ≥ 18 years.
  3. Histologically documented, incurable, locally advanced or metastatic cancer.
  4. Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC.
  5. Patients should have no available therapy likely to convey clinical benefit.
  6. Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL.
  7. Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
  8. Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.
  9. ECOG Performance Status ≤ 1.
  10. Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
  11. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.

Phase II

Patients must meet the following criteria for inclusion into the study:

  1. Patients must be able to provide documented voluntary informed consent.
  2. Male or female patient ≥ 18 years.
  3. Histologically documented, incurable, locally advanced or metastatic cancer.
  4. Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC.
  5. Regarding previous therapy:

    5.1. Cohort 1: HER2 positive (IHC 2+ with FISH confirmation and Immunohistochemistry (IHC 3+) breast cancer: patients should have progressed after at least 2 previous HER2 directed regimens in metastatic disease with approved therapies.

    5.2. Cohort 2: HER2 positive (IHC 2+ with FISH confirmation and IHC 3+) gastric cancer: patients should have progressed after at least 1 previous HER2 directed regimens in metastatic disease with approved therapies.

    5.3. Cohort 3: HER2 low expressing (IHC 1+ and IHC 2+ without FISH confirmation) breast cancer: patients should have no available therapy likely to convey clinical benefit.

    5.4. Cohort 4: all cancers other than breast cancer with low HER2 expression (IHC 1+ and IHC 2+ without FISH confirmation) and HER2 positive (IHC 2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer: patients should have no available therapy likely to convey clinical benefit.

  6. Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL.
  7. Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
  8. Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.
  9. ECOG Performance Status ≤ 1.
  10. Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
  11. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.

Exclusion Criteria:

Phase I:

  1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
  2. History of Grade ≥ 3 hypersensitivity reaction to trastuzumab.
  3. History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued.
  4. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.
  5. Require supplemental oxygen for daily activities.
  6. Documented Grade ≥ 2 peripheral neuropathy.
  7. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug.
  8. Any experimental therapy within 4 weeks of first infusion of study drug.
  9. Any major surgical procedure within 4 weeks of first infusion of study drug.
  10. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded.
  11. Have known prior positive test results for human immunodeficiency virus.
  12. Uncontrolled hypertension or diabetes.
  13. Pregnancy or lactation.
  14. Resting corrected QT interval (QTc) > 470 ms at baseline.
  15. Left ventricular ejection fraction (LVEF) < 45% determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
  16. Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.

Phase II:

  1. Any patient who was treated in the Phase I part of this study.
  2. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
  3. History of Grade ≥ 3 hypersensitivity reaction to trastuzumab.
  4. History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued.
  5. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.
  6. Require supplemental oxygen for daily activities.
  7. Documented Grade ≥ 2 peripheral neuropathy.
  8. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug.
  9. Any experimental therapy within 4 weeks of first infusion of study drug.
  10. Any major surgical procedure within 4 weeks of first infusion of study drug.
  11. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded.
  12. Have known prior positive test results for human immunodeficiency virus.
  13. Uncontrolled hypertension or diabetes.
  14. Pregnancy or lactation.
  15. Resting QTc > 470 ms at baseline.
  16. LVEF < 45% determined by ECHO or MUGA scan.
  17. Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Clinical Trials Info at Kluspharma 609-662-1913 Clinicaltrialinfo@kluspharma.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03602079
Other Study ID Numbers  ICMJE KlusPharma
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Klus Pharma Inc.
Study Sponsor  ICMJE Klus Pharma Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Jordi Rodon Ahnert, MD, PhD MD Anderson
PRS Account Klus Pharma Inc.
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP